Back to Search
Start Over
β-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant T H 2/T H 17 responses.
- Source :
-
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2017 Jan; Vol. 139 (1), pp. 54-65.e8. Date of Electronic Publication: 2016 Apr 20. - Publication Year :
- 2017
-
Abstract
- Background: Allergic sensitization to fungi has been associated with asthma severity. As a result, it has been largely assumed that the contribution of fungi to allergic disease is mediated through their potent antigenicity.<br />Objective: We sought to determine the mechanism by which fungi affect asthma development and severity.<br />Methods: We integrated epidemiologic and experimental asthma models to explore the effect of fungal exposure on asthma development and severity.<br />Results: We report that fungal exposure enhances allergen-driven T <subscript>H</subscript> 2 responses, promoting severe allergic asthma. This effect is independent of fungal sensitization and can be reconstituted with β-glucan and abrogated by neutralization of IL-17A. Furthermore, this severe asthma is resistant to steroids and characterized by mixed T <subscript>H</subscript> 2 and T <subscript>H</subscript> 17 responses, including IL-13 <superscript>+</superscript> IL-17 <superscript>+</superscript> CD4 <superscript>+</superscript> double-producing effector T cells. Steroid resistance is dependent on fungus-induced T <subscript>H</subscript> 17 responses because steroid sensitivity was restored in IL-17rc <superscript>-/-</superscript> mice. Similarly, in children with asthma, fungal exposure was associated with increased serum IL-17A levels and asthma severity.<br />Conclusion: Our data demonstrate that fungi are potent immunomodulators and have powerful effects on asthma independent of their potential to act as antigens. Furthermore, our results provide a strong rationale for combination treatment strategies targeting IL-17A for this subgroup of fungus-exposed patients with difficult-to-treat asthma.<br />Competing Interests: The authors have declared that no conflict of interest exists. AL Budelsky is a paid employee and stockholder in Amgen, Inc.<br /> (Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Air Pollutants immunology
Animals
Anti-Inflammatory Agents therapeutic use
Antigens, Dermatophagoides immunology
Asthma drug therapy
Asthma epidemiology
Asthma pathology
Child
Child, Preschool
Dexamethasone therapeutic use
Drug Resistance immunology
Environmental Exposure
Female
Glucocorticoids therapeutic use
Humans
Infant
Interleukin-17 blood
Interleukin-17 immunology
Lectins, C-Type genetics
Lung drug effects
Lung immunology
Lung pathology
Male
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Knockout
Prevalence
Receptors, Interleukin genetics
Allergens immunology
Asthma immunology
Fungi immunology
Th17 Cells immunology
Th2 Cells immunology
beta-Glucans immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6825
- Volume :
- 139
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The Journal of allergy and clinical immunology
- Publication Type :
- Academic Journal
- Accession number :
- 27221135
- Full Text :
- https://doi.org/10.1016/j.jaci.2016.02.031